10.1016/j.mce.2020.110921 31 LiZ.LiS.WangN.XueP.LiY
Healthcare professionals can provide tailored dosing plans that can be adjusted throughout treatment, monitor progress, and offer guidance on lifestyle changes that may support long-term success
Patients who strength train consistently lose more fat and less muscle than those who don't
External resources PubMed: AOD 9604 lipolytic activity study - Research on AOD 9604 mechanism of action in adipose tissue New England Journal of Medicine: STEP 1 Trial - Landmark semaglutide weight loss trial with 1,961 participants FDA: Semaglutide safety information - Official FDA information on approved semaglutide formulations WADA Prohibited List - Current prohibited substances list including growth hormone fragments ClinicalTrials.gov: Semaglutide trials - Registry of ongoing and completed semaglutide clinical trials Choosing between AOD 9604 and semaglutide is ultimately a decision that depends on your individual circumstances, health status, and weight loss goals
Keep tablets in original packaging
The favorable safety profile of tesofensine, demonstrated in this trial and previous studies, adds to the potential of Tesomet in treating conditions like Prader-Willi syndrome and hypothalamic obesity
